Press Releases

Official press releases

Experimental HIV treatment models highlight success and pinpoint obstacles to expanding care in African countries

posted on


Wednesday, 20 July
13:00PM SAST

Durban, South Africa – Researchers in developing countries with high burdens of HIV infection are developing promising new strategies to advance towards global HIV treatment targets, the 21st International AIDS Conference in Durban South Africa has heard.

The UNAIDS fast track strategy seeks to ensure that 90% of HIV-positive people know their status, 90% are able to access antiretroviral treatment (ART), and 90% of those on treatment attain viral suppression, by the year 2020. Studies on treatment expansion in several southern and East African countries presented at AIDS 2016 provide new insights on how to acheive the 90-90-90 objectives, while also identifying some critical obstacles to overcome.

Anton Pozniak, Clinical Service Director of the HIV Unit at the Chelsea and Westminster Hospital in London and Treasurer of the International AIDS Society, highlighted the scope of the task by referring to statistics from the UNAIDS Prevention Gap Report, which estimate that 57% of people living with HIV know their status currently, 46% of all people living with HIV have access to ART, and only 38% of people living with HIV have achieved viral suppression.
“The limited success of efforts to provide broader access to treatment are reflected in unacceptable mortality rates and a decreasing momentum in the reduction of new HIV infections globally,” commented Pozniak. “The research reported here offers valuable insight into the opportunities and the challenges we face in gearing up delivery systems to meet our HIV treatment goals.”
Two studies presented here focus on the impact of the ‘test and treat’ approach to ARV therapy on expanding treatment access and improving retention in care. Under the test and treat model, the administration of ARVs begins as soon as possible after individuals learn they are HIV-positive, without regard to CD4 counts.
“Interim results from the SEARCH study, conducted in 164 communities in rural Kenya and Uganda, showed a significant advance toward achieving the UNAIDS 90-90-90 target among adults living with HIV,” said Maya L. Petersen, Associate Professor of Biostatistics and Epidemiology, Berkeley School of Public Health. “The study employed a community-based multi-disease approach to HIV testing combined with a patient-centred ‘test and treat’ model of ART. At the start of SEARCH, 45% of the HIV-positive population had viral loads below 500 copies/ml. Two years later, following the study intervention, 81% were virally suppressed.”
In contrast, the TasP study in 22 rural South African communities found little difference in viral suppression between those offered therapy through the test and treat approach, and those provided with standard ART according to national guidelines. Nine of 10 patients in both groups achieved viral suppression, Professor François Dabis of the Institute of Public Health, Epidemiology and Development at the University of Bordeaux reported. But the study identified a weakness in the middle of the 90-90-90 cascade – only one in three individuals newly diagnosed as HIV-positive was linked to treatment clinics within six months of testing.
The challenge of ensuring linkage to care after HIV testing was addressed in another study, conducted in Swaziland. A combination of interventions – such as CD4 count testing immediately after receipt of HIV test results, use of mobile phones to remind patients of their appointments, and non-cash financial incentives – resulted in a 50% increase in prompt linkage to care and retention in the treatment programme.
Two studies presented here highlighted commonly-encountered challenges for treatment programmes in developing countries:

  • The high proportion of people with HIV who seek treatment at an advanced stage of infection, when the immune system is severely affected and the risk of mortality is high.
  • A growing number of adolescents who have been on ART for prolonged periods and show declining viral suppression.

The REALITY trial, spanning Kenya, Malawi, Uganda, and Zimbabwe, compared mortality rates when two different models of care were provided to adults and children who presented for ART with severely compromised immunity (CD4<100 cells/mm³). Half the group (899 people) were provided the standard level of care, including ARVs and the antibiotic cotrimoxazole. The other half (906 people) received the standard treatment plus enhanced prophylaxis for bacterial infections, tuberculosis, cryptococcal meningitis, oral/oesophageal candida, and parasitic worms.
REALITY demonstrated that enhanced prophylaxis saved lives. In the first 24 weeks of treatment, there were 108 deaths in the group receiving standard care, compared to 80 among those receiving enhanced prophylaxis. Within 48 weeks the respective figures increased to 127 and 98 deaths, respectively.
“Providing enhanced prophylaxis at the start of ART reduced early mortality by 25% among patients with advanced HIV disease,” said James Hakim, Professor of Medicine at the University of Zimbabwe College of Health Sciences. “When the gains are spread across the entire treatment programme, we are looking at saving three lives for every 100 patients we treat. Policy-makers should consider introducing this low-cost broad infection package for all HIV-positive patients presenting with very low CD4 counts.”
Researchers analysing records from South Africa’s National Health Laboratory Service (NHLS) found that the number of children and adolescents receiving ART in the country increased tenfold between 2004 and 2011, and twentyfold between 2012 and 2014, leading to the existence of a 'youth treatment bulge'. The bulge is mainly due to historic deficiencies in the prevention of mother-to-child transmission of HIV in the country, which resulted in substantial numbers of babies being born with HIV, but surviving due to ART. Now that PMTCT is universally available in South Africa, the bulge is expected to shrink over the coming decade.
The study also found that viral suppression among young people decreased with age. While 71% of children aged five to nine years were virally suppressed, the rate among those aged 10 to 14 years dropped to 65%, and only 61% of those in the 15-19-year age group achieved viral supression.
“The number of adolescents accessing HIV care is increasing, yet this group experiences poorer treatment outcomes than other age groups,” said Mhairi Maskew, Senior Researcher in the Health Economics and Epidemiology Research Office, Faculty of Health Sciences at Wits University. “Programmes prioritising this key population require investment at the national level.”


About the International AIDS Conference
The International AIDS Conference is the largest conference on any global health or development issue. First convened during the peak of the AIDS epidemic in 1985, this conference continues to provide a unique forum for the intersection of science and advocacy, and an opportunity to strengthen policies and programmes to ensure an evidence-based response to the epidemic. The conference also serves as a focal point to intensify political and financial commitments to AIDS. The 21st International AIDS Conference (AIDS 2016) is being held in Durban, South Africa (18-22 July 2016).
AIDS 2016 Conference Organizers
AIDS 2016 is organized by the International AIDS Society in partnership with the Global Network of People Living with HIV (GNP+); the International Council of AIDS Service Organizations (ICASO); the International Community of Women Living with HIV/AIDS (ICW Global), and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Non-permanent partners are ICW Eastern Africa and the Men who Have Sex with Men Global Forum (MSMGF). Local partners are the South Africa National AIDS Council, the Department of Health for the Republic of South Africa, and the South African Medical Research Council (SAMRC). Regional partners are the AIDS Rights Alliance for Southern Africa (ARASA), Enda Santé, and Réseau Africain des Praticiens Assurant la Prise en Charge Médicale des Personnes Vivant avec le VIH/SIDA (RESAPSI).
About the International AIDS Society
Founded in 1988, the International AIDS Society (IAS) is the world’s largest association of HIV professionals, with members from more than 180 countries. IAS members work on all fronts of the global response to AIDS and include researchers, clinicians, policy and programme planners, and public health and community practitioners.

Media Contacts:
Mandy Sugrue, +27.823.346.192              Maria Djordjevic, +27.823.346.192
[email protected]                   [email protected]
AIDS 2016: Join the Conversation
Get the latest conference updates and share your thoughts and ideas through the AIDS 2016 social media channels.

  • Tweet along with us – @AIDS_conference and @iasociety – using #AIDS2016 to keep the conversation going.
  • Like AIDS 2016 on Facebook – and stay in touch with the latest conference updates and developments.
  • Check us out on Instagram to see photos as they are happening. 

Visit our YouTube channel to see featured videos and other content.


| Return

Third party press releases

Collaborative Canadian study on HIV, housing and health wins 2016 Robert Carr Research Award
27 July 2016

Ten organizations receive Red Ribbon Award for outstanding community leadership on AIDS
27 July 2016

Founding Patron, Prince Harry, and Sir Elton John speak out about empowering youth at the International AIDS Conference in Durban
21 July 2016

LetsStopAIDS Celebrates 10 Years of Youth-HIV programming in KwaZulu-Natal
Additional info
21 July 2016

India Endangering the Global AIDS Response: Constitutional Court Justice, Human Rights Activists, and Medical Groups Raise Alarm
21 July 2016

Elton John AIDS Foundation and PEPFAR Announce Inaugural LGBT Fund Recipients
20 July 2016

Fast-Track Cities Unveil 90-90-90 and HIV Care Continuum Data at AIDS 2016 Demonstrating Progress Towards Goal of Ending AIDS as a Public Health Threat by 2030
20 July 2016

A Conversation with Amb. Birx & Minister Motsoaledi in Durban
20 July 2016

The Lancet: Mass imprisonment of drug users driving global epidemics of HIV, hepatitis, and tuberculosis
19 July 2016

The Lancet: Criminal justice reforms could reduce national HIV and tuberculosis burdens in sub-Saharan Africa
19 July 2016

Update on investigational prime boost HIV-1 vaccine regimen in development at the Janssen Pharmaceutical Companies of Johnson & Johnson
19 July 2016

Johnson & Johnson press availability: HIV prevention efforts and update on global public health Africa operations
19 July 2016

Unprecedented Funding Drop Threatens Global AIDS Response Experts Warn of Significant Epidemiological Impact
19 July 2016

ONE issues warning to African leaders attending IAC: Step up fight against HIV and AIDS or risk millions of lives
18 July 2016

United Nations Secretary-General Ban Ki-moon invokes the memory of Madiba and calls for Universal Access to Medicines at International Aids Conference
18 July 2016

PEPFAR and DREAMS Partners Announce Winners of the $85 Million DREAMS Innovation Challenge
18 July 2016

PEPFAR Welcomes the Return of the International HIV/AIDS Conference to Africa
18 July 2016

mothers2mothers Announces Reduction of Mother-to-Child Transmission of HIV to 2.1% among Programme Participants: Peer Mentor Approach Effective and Transferable Across Health Issues
18 July 2016

ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV
18 July 2016

United Nations Secretary-General Ban Ki-moon to discuss the High-Level Panel on Access to Medicines
16 July 2016

EJAF Founder Elton John and Prince Harry to Host Special Session at 2016 International AIDS Conference
14 July 2016

Sentebale’s founding patron, Prince Harry heads to Durban to talk at the International AIDS Conference
14 July 2016